^
Association details:
| Biomarker: | ALK E1129V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Excerpt:
All those patients with tumors harboring common ALK resistance mutations, including E1129V, L1196M, C1156Y, I1171T and F1174V, had partial responses with ceritinib, while a patient with G1202R did not respond
DOI:
10.2147/DDDT.S113500
